Show results for
Refine by
Medical Launches Inaugural Esg Report Articles & Analysis
31 news found
An innovative Australian micro screw created to help significantly reduce complications in the management of orthopaedic injuries and the fixing of fractures in the hand and wrist will be used in a world-first operation in Brisbane by internationally-renowned hand surgeon Dr Greg Couzens on Wednesday 30 January. The Field Micro Screw by Brisbane med-tech start-up Field Orthopaedics has already ...
HINGHAM, Mass., Aug. 18, 2022 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), announced that it will be presenting the Company’s Self-Cleaning Shunt (SCS) at the 16th Asian Australasian Congress of Neurological Surgeons (AACNS). The AACNS is hosted by the Israel Neurosurgery Society and is being held from September 6th – 8th in Jerusalem, Israel. Dr Gustavo Rajz, Head of ...
Ended the quarter with $47.2 million in cash and investments – expected to fund operations through the end of 2024, including release of topline SAVVE pivotal trial data IRVINE, CA / August 3, 2022 / enVVeno Medical Corporation (NASDAQ:NVNO) (“enVVeno” or the “Company”), a company setting new standards of care for the treatment of venous disease, today provided a ...
TORONTO, June 09, 2022 (GLOBE NEWSWIRE) -- Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical device company focused on the development and commercialization of innovative surgical technologies for single access robotic-assisted surgery (RAS), today announced the voting results form the company’s Annual and Special Meeting of its shareholders held on Wednesday June 8, 2022. All of ...
Helius Medical Technologies, Inc. (Nasdaq: HSDT) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that, effective May 23, 2022, its independent directors approved equity awards under Helius’ 2021 Inducement Plan, as a material inducement to four individuals entering into employment with the Company. The equity awards ...
AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the “Company”), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, today reported financial results for its first quarter ended March 31, 2022. Financial Highlights and Recent Updates: Reported commercial revenue, ...
TORONTO--(BUSINESS WIRE)-- Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical device company focused on the development and commercialization of innovative surgical technologies for single access robotic-assisted surgery (RAS), today announced financial results for the three months ended March 31, 2022. “The entire team is focused on driving performance and progress supporting our IDE ...
Ended the quarter with $51.3 million in cash – expected to fund operations through the end of 2024 including release of topline pivotal trial data Ongoing advancement of SAVVE U.S pivotal trial with 20 sites available to enroll patients Progress on development of second device for the treatment of venous disease expected to be unveiled in mid-2022 IRVINE, CA / May 2, 2022 / enVVeno ...
Ended the Year With $55 Million in Cash Expected To Fund Operations Through the End of 2024 Including Release of Topline Pivotal Trial Data Nine (9) VenoValve Surgeries Successfully Completed and 16 Clinical Sites Currently Active in Ongoing SAVVE U.S Pivotal Trial Continued Advancement in Development of Second Device for the Treatment of Venous Disease Expected To Be Unveiled in Mid-2022 ...
HINGHAM, Mass., March 31, 2022 (GLOBE NEWSWIRE) -- The operational momentum that Microbot Medical Inc. (Nasdaq: MBOT) experienced at the end of 2021 has continued well into the 2022 first quarter. The Company filed its pre-submission package for the LIBERTY® Robotic System with the U.S. Food and Drug Administration (FDA), addressing the regulatory pathway for the LIBERTY® Robotic System. ...
Outset Medical, Inc. (Nasdaq: OM) (“Outset” or the “Company”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today reported financial results for the fourth quarter and full year ended December 31, 2021. The Company also announced that Leslie Trigg has been appointed Chair of the Board of Directors in ...
Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that it will release financial results for the fourth quarter and full year of 2021 after the close of trading on Wednesday, February 16, 2022. On the same day, at 2:00 pm Pacific Time (5:00 pm Eastern ...
“We are extremely pleased that Fierce Pharma Online reviewed EsoCap’s unique and innovative topical drug delivery system to the esophagus and the current Phase II program, as well as further use of its platform in additional indications,” said Isabelle Racamier, EsoCap AG CEO. “This strengthens our resolve to bring a major improvement to the lives of patients using ...
Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced the release of its inaugural Environmental, Social, and Governance (ESG) report highlighting its ESG-related programs, priorities, goals, and performance. “At Outset, our ESG journey is rooted in our ...
One complete response, and a disease control rate of 64% with stable disease for ≥16 weeks in two patients, as of the data cutoff Data presented today at the International Liver Cancer Association meeting at 12:25 p.m. CET Adaptimmune Therapeutics plc (Nasdaq: ADAP), a leader in cell therapy to treat cancer, announced updated data from its Phase 1 ADP-A2AFP trial for patients with liver ...
If anyhow, your liver stops working properly, you may need a liver transplant. Liver Transplant India is generally recommended if you have a last-stage liver disease, which is chronic liver failure. This is a life-threatening and serious liver disease, and this is be caused by many liver conditions. For instance, cirrhosis is one of the common causes of end-stage liver disease. It is one of the ...
Adagio Medical, Inc., a leading innovator in catheter ablation technologies for atrial fibrillation (AF) and ventricular tachycardia (VT), announced the results of its CryoCure-2 ultra-low temperature cryoablation (ULTC) prospective multi-center study in patients with AF at the 2021 Heart Rhythm Society Annual Meeting. The late-breaking clinical trials presentation was delivered by Dr. Tom De ...
Alleviant Medical Inc., a privately-held medical device company, today announced one-month and three-month follow up data from the first in human clinical study (ALLEVIATE-HF-1) of its technology for the treatment of heart failure with preserved ejection fraction (HFpEF). The Alleviant System is a novel transcatheter device for the creation of a therapeutic interatrial shunt without a permanent ...
Applying non-invasive electrical stimulation to the expiratory abdominal muscles may reduce abdominal muscle atrophy and markedly reduce the number of days adult patients require mechanical ventilation – a potentially important finding for weaning ventilated patients, including seriously ill COVID-19 patients, and improving patient outcomes. Liberate Medical today announced the results of ...
Mark Barrish, CEO of Moray Medical, gave an interview to Medgadget, a well-known source for international medical technology news, health care trends, and medical research. Reporter Conn Hastings elicited clear, precise answers to questions ranging from the basics of heart valve failure to the advantages of augmented reality in Moray’s surgical ...